On February 14, 2024, Edesa Biotech, Inc. (EDSA) announced financial results for the first quarter of fiscal year 2025 that ended December 31, 2024 and provided a business update. The company recently announced it raised $15 million in a private placement with healthcare-focused institutional investors. The funds will be utilized to advance its anti-CXCL10 monoclonal antibody, EB06, for the treatment of vitiligo. We anticipate an IND being filed before the end of 2025 for EB06 such that a Phase 2 clinical trial can initiate in 2026. Results from that study should be available in 12-18 months following regulatory clearance of the IND.
